Inactive Instrument
Peregrine Pharmaceuticals Share Price Nasdaq
Stocks
US7136613046
Pharmaceuticals
| Market Cap | 799M 684M 640M 586M 1.1B 76.44B 1.11B 7.57B 2.95B 38.4B 3B 2.93B 127B | P/E 2023 |
2,007x | P/E 2024 | -3.42x |
|---|---|---|---|---|---|
| Enterprise Value | 964M 826M 773M 707M 1.33B 92.26B 1.35B 9.13B 3.56B 46.34B 3.62B 3.54B 153B | EV / Sales 2023 |
8.58x | EV / Sales 2024 | 4.64x |
| Free-Float |
98.58% | Yield 2023 * |
-
| Yield 2024 | - |
| 1 day | -2.83% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 14/09/2025 | |
Richard McAvoy
DFI | Director of Finance/CFO | - | 31/05/2026 |
David Stewart
CTO | Chief Tech/Sci/R&D Officer | - | 31/10/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.83% | +7.69% | - | - | 799M | |
| +0.90% | +3.80% | +41.49% | -0.78% | 83.28B | |
| +8.86% | +129.20% | +435.14% | +24.85% | 57.94B | |
| -1.69% | +23.30% | -22.30% | -36.29% | 57.77B | |
| -1.46% | +0.19% | -2.06% | +30.50% | 51.75B | |
| +1.74% | +4.43% | +12.37% | +169.64% | 49.35B | |
| +1.13% | +3.31% | +55.61% | -17.57% | 32.03B | |
| +0.46% | +6.37% | +50.29% | +97.27% | 25.91B | |
| +1.19% | +9.17% | +2.97% | +230.86% | 22.74B | |
| -0.30% | +4.45% | +58.29% | +118.84% | 16.87B | |
| Average | +0.80% | +20.47% | +70.20% | +68.59% | 44.18B | |
| Weighted average by Cap. | +1.43% | +24.98% | +80.52% | +46.37% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 149M 128M 120M 110M 206M 14.28B 208M 1.41B 551M 7.17B 560M 548M 23.73B | 140M 120M 112M 103M 193M 13.39B 195M 1.32B 517M 6.72B 525M 514M 22.24B |
| Net income | 560K 480K 449K 411K 771K 53.58M 781K 5.3M 2.07M 26.92M 2.1M 2.06M 89.03M | -141M -121M -113M -103M -194M -13.47B -196M -1.33B -520M -6.77B -529M -517M -22.38B |
| Net Debt | 151M 130M 121M 111M 208M 14.47B 211M 1.43B 558M 7.27B 568M 555M 24.04B | 165M 142M 133M 121M 228M 15.82B 231M 1.57B 611M 7.95B 621M 607M 26.28B |
Employees
-
Sector
Pharmaceuticals
